Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.
Objective: To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab.
Objective: Report the safety and tolerability of ofatumumab in RMS after extended treatment up to 3.5 years.
Novartis announced new post hoc data showing the efficacy and safety of Kesimpta (ofatumumab), a targeted B-cell therapy, in patients with relapsing forms of multiple sclerosis (RMS) who are newly diagnosed as well as ongoing safety study findings .
Merck KGaA announced the Multiple Sclerosis Journal publication of data outlining the effects of Mavenclad (cladribine tablets) treatment on two...
Objectives: To assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed, treatment-naive (RDTN) participants from ASCLEPIOS.
Real-world and clinical evidence demonstrates that Tecfidera (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients...
Takeda announced that the FDA has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Novartis announced data demonstrating the safety of Kesimpta (ofatumumab) over extended exposure (about 3.5 years) in patients with relapsing forms of multiple sclerosis (RMS). LITHIOS Phase IIIb open-label extension study data based on about 3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there was no apparent association between IgG levels and the risk of serious infections.
Purpose of review: The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer.